000			02213 a2200637 4500
005			20250516144236.0
264		0	_c20140219
008			201402s 0 0 eng d
022			_a1539-2864
024	7		_a10.1097/IAE.0b013e318285cf92 _2doi
040			_aNLM _beng _cNLM
100	1		_aHautamäki, Asta
245	0	0	_aInterleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. _h[electronic resource]
260			_bRetina (Philadelphia, Pa.) _cOct 2013
300			_a1815-27 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlleles
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aBevacizumab
650	0	4	_aComplement C3 _xgenetics
650	0	4	_aComplement Factor H _xgenetics
650	0	4	_aExudates and Transudates
650	0	4	_aFemale
650	0	4	_aGenotype
650	0	4	_aHumans
650	0	4	_aInterleukin-8 _xgenetics
650	0	4	_aIntravitreal Injections
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPharmacogenetics
650	0	4	_aPolymerase Chain Reaction
650	0	4	_aPolymorphism, Single Nucleotide
650	0	4	_aPromoter Regions, Genetic _xgenetics
650	0	4	_aProspective Studies
650	0	4	_aProteins _xgenetics
650	0	4	_aTomography, Optical Coherence
650	0	4	_aTreatment Outcome
650	0	4	_aVascular Endothelial Growth Factor A _xantagonists & inhibitors
650	0	4	_aVisual Acuity _xphysiology
650	0	4	_aWet Macular Degeneration _xdiagnosis
700	1		_aKivioja, Jarno
700	1		_aVavuli, Satu
700	1		_aKakko, Sakari
700	1		_aSavolainen, Eeva-Riitta
700	1		_aSavolainen, Markku J
700	1		_aLiinamaa, M Johanna
700	1		_aSeitsonen, Sanna
700	1		_aOnkamo, Päivi
700	1		_aJärvelä, Irma
700	1		_aImmonen, Ilkka
773	0		_tRetina (Philadelphia, Pa.) _gvol. 33 _gno. 9 _gp. 1815-27
856	4	0	_uhttps://doi.org/10.1097/IAE.0b013e318285cf92 _zAvailable from publisher's website
999			_c22668093 _d22668093